KUALA LUMPUR, Sept 18 -- InnovaHealth Partners, LP (InnovaHealth) and Koelis SAS (Koelis) jointly announced with Medevice Partners that InnovaHealth has made a growth equity investment in Koelis and acquired majority interest in the company.
“In transforming the way prostate cancer is diagnosed and treated, we see enormous potential to bring Koelis’ differentiated technology to scale in a US$2.5 billion global market where it addresses significant unmet clinical needs,” said InnovaHealth president and chief executive officer, Mortimer ‘Tim’ Berkowitz III.
Koelis is a leadership innovator in the market for image-guided systems for prostate cancer diagnosis and treatment.
Its products have regulatory clearances and have been commercialised in the United States (US), Europe and most Asian markets.
The Koelis Trinity™ System offers market-leading features including ‘fusion’ imaging, organ tracking, robotic assistance and focal therapy.
Based in the US, InnovaHealth is the leading specialist medical device growth private equity firm. It manages approximately US$200 million and has over 100 years of experience investing in the global medical device market. (US$1 = RM4.18)
-- BERNAMA
-- BERNAMA
No comments:
Post a Comment